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Abstract
Objectives To evaluate iceball margins after magnetic reso-
nance (MR)-guided focal salvage prostate cryoablation and
determine the correlation with local outcome.
Methods A retrospective review was performed on 47 pa-
tients that underwent percutaneous MR-guided focal
cryoablation for biopsy-proven locally recurrent prostate can-
cer after primary radiotherapy. Preprocedural diagnostic and
intraprocedural MR images were analysed to derive three-
directional iceball margins. Local tumour progression after
cryoablation was defined as evident tumour recurrence on
follow-up MRI, positive MR-guided biopsy or biochemical
failure without radiological evidence of metastatic disease.
Results Mean iceball margins were 8.9 mm (range −7.1 to
16.2), 10.1 mm (range 1.1–20.3) and 12.5 mm (range −1.5
to 22.2) in anteroposterior, left–right and craniocaudal direc-
tion respectively. Iceball margins were significantly smaller
for tumours that were larger (P = .008) or located in the pos-
terior gland (P = .047). Significantly improved local
progression-free survival at 1 year post focal cryoablation
was seen between patients with iceball margin >10 mm
(100%), 5–10 mm (84%) and <5 mm (15%) (P < .001).
Conclusions Iceball margins appear to correlate with local
outcome following MR-guided focal salvage prostate
cryoablation. Our initial data suggest that freezing should be
applied at minimum 5 mm beyond the border of an MR-
visible recurrent prostate tumour for successful ablation, with
a wider margin appearing desirable.
Key points
• Shortest iceball margin most often occurred in anteroposterior
direction
• Margins were smaller in tumours that were larger or poste-
riorly located
• Minimum iceball margin was a predictor of early local tu-
mour progression
• A minimum 5-mm margin seems required for effective cryo-
ablation of recurrent PCa
Keywords Ablationmargin . Cryoablation .MRI . Prostate
cancer . Local recurrence
Introduction
Prostate cancer (PCa) recurrence following radiotherapy (RT)
is not uncommon, with an estimated 10–60% of patients
experiencing biochemical failure within 5–10 years after treat-
ment [1, 2]. There has been no consensus on optimal manage-
ment of this patient group with a majority of patients receiving
androgen deprivation therapy (ADT) [3]. Treatment options
with curative intent are limited and include salvage radical
prostatectomy (RP), brachytherapy, high-intensity focused ul-
trasound and cryoablation [4].
Salvage RP is generally regarded as a challenging proce-
dure to perform and has been associated with high complica-
tion risks [5]. Whole-gland salvage cryoablation has emerged
as an accepted treatment alternative, with acceptable
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oncological outcomes and side effects [6, 7]. However, com-
plications such as erectile dysfunction (72–100%), inconti-
nence (2.6–73%) and rectal fistula (0–3.4%) may still exist
[8, 9]. In an attempt to reduce treatment morbidity, several
studies have been exploring the concept of partial cryoablation
for biopsy-proven unilateral recurrences [9–11]. At the same
time, advancements in prostate magnetic resonance (MR) im-
aging have enabled the accurate detection and localization of
locally recurrent PCa after previous irradiation [12, 13].
Additionally, MRI can also be used to intraoperatively guide
cryoablation procedures [14, 15], opening new possibilities
for focal salvage approaches.
In a recent study the feasibility of MR-guided focal
cryoablation was shown in ten patients with locally recurrent
PCa after primary RT [16]. Although initial short-term results
were promising, three patients developed local tumour recur-
rence at the site of ablation within 6–12months after treatment
and the authors concluded that these tumours were most prob-
ably undertreated. Findings from in vitro and in vivo animal
studies on renal cryoablation have shown that lethal tempera-
tures may be achieved at approximately 5–6 mm within the
edge of the iceball [17, 18]. For prostate cryoablation, some
authors have suggested freezing to be applied 2–3mm beyond
the tumour boundary to reach an end temperature of −20 °C,
which has been associated with tissue necrosis [19]. However,
limited clinical data is presently available verifying these rec-
ommendations with patient outcomes and a consensus on the
margin needed for effective cryoablation of recurrent PCa has
not been established. The purpose of the present study was to
evaluate iceball margins after MR-guided focal salvage pros-
tate cryoablation and determine the correlation with local
outcome.
Materials and methods
In July 2016, a total of 61 consecutive patients were identified
that underwent MR-guided focal cryoablation for locally re-
current PCa at our institution between May 2011 and
July 2015 and were at least 1 year after treatment. Ten patients
were excluded because they had undergone previous salvage
treatment. Additionally, three patients who underwent radical
prostatectomy as primary treatment and one patient who was
treated in two separate sessions were excluded. A total of 47
patients (median age 66 years, age range 52–79) underwent
MR-guided focal cryoablation for local PCa recurrence after
primary RT and were included in this retrospective study.
Informed consent to use anonymized data for analysis was
obtained in all patients.
Patients were eligible for focal cryoablation on the basis of
biopsy-proven MRI-visible local PCa recurrence without ra-
diologic evidence of metastatic disease. The final decision to
perform cryoablation was made at the multidisciplinary board
meeting. Focal cryoablation was performed at a median of
5 years (range 1–18) after primary RT. Prior to treatment, all
patients underwent 3-T multi-parametric MR imaging
(mpMRI) with a pelvic phased-array coil (n = 43) or
endorectal coil (n = 4), consisting of T2-weighted (T2w),
diffusion-weighted (DWI) and dynamic contrast-enhanced
(DCE) imaging, to localize the recurrence and measure visible
tumour volume as well as an abdominal and pelvic staging
MRI to exclude nodal or bone marrowmetastases. There were
no restrictions related to pretreatment prostate specific antigen
(PSA) level, Gleason score, prior history of ADT, tumour
volume or local extent. The National Comprehensive Cancer
Network (NCCN) guidelines were used to categorize patients
into low-to-intermediate and high-risk groups [20]. High-risk
status was assigned when any of the following criteria were
met: cancer stage ≥ T3a, Gleason ≥8 or PSA ≥20 ng/ml. A
summary of patient demographics is included in Table 1.
Cryoablation procedures
Patients were treated under general anaesthesia in a 1.5-Tor 3-
T MR system (Magnetom Avanto or Skyra, Siemens,
Erlangen, Germany). All procedures were performed by one
of two interventional radiologists (J.F. or S.J.) each with more
than 6 years of experience in prostate interventions. A urethral
warming catheter and rectal balloon were inserted to protect
the urethra and rectal wall. A transperineal approach was used
to place multipleMR-compatible cryoprobes (MRI IceSeed or
IceRod, Galil Medical, Yokneam, Israel) centrally in the target
region under real-time MR image guidance. Type, number
and position of cryoprobes were chosen at the discretion of
the performing physician. Cryoablation was performed using
an MR-compatible cryoablation device (MRI-SeedNet; Galil
Medical, Yokneam, Israel). Two 10-min freezing cycles sep-
arated by 2-min passive and 1-min active thaw were applied
under continuous T1-weighted gradient echo MR monitoring
[21, 22]. The intraprocedural images were used to modulate
the size and shape of the iceball by regulating the gas flow to
each individual cryoprobe so as to cover the entire tumour
while avoiding contact between the iceball and rectal wall.
Upon completion of the ablation, all cryoprobes were thawed
and removed. All intraprocedural complications were docu-
mented. Postprocedural complication data, functional out-
comes and quality-of-life metrics were not part of the present
work and will be reported elsewhere.
Image review and follow-up
All preprocedural and intraprocedural images were retrospec-
tively reviewed by one prostate interventional radiologist (S.J.)
using medical image visualization software (MeVisLab,
Fraunhofer, Bremen, Germany). Treated tumours were anno-
tated on the pretreatment diagnostic mpMRI using information
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from all available MR sequences to delineate the tumour
boundary. Tumour locations were classified as anterior when
more than 50% located in the ventral half of the prostate or
posterior when located more than 50% in the dorsal half of the
prostate.
Intraprocedural MR images obtained at the end of the second
freeze cycle were used to annotate each corresponding iceball.
MeVisLab software was used register each annotated iceball to
the centre of the corresponding annotated tumour. Maximum
tumour and corresponding iceball sizes were derived from the
annotated regions in anteroposterior, left–right and craniocaudal
direction as well as total tumour and iceball volumes. The iceball
margin was then defined as the margin calculated by subtracting
the iceball’s radius from the corresponding lesion radius in each
direction (Fig. 1). The minimum iceball margin was defined as
the shortest margin in each patient. Undertreated tumours were
defined by a negative margin between the iceball and tumour.
Finally, the position of the iceball relative to the tumour was
recorded: a well-centred iceball covered the entire tumour in
the axial plane at the centre of the lesion.
Postprocedural follow-up (median 24 months, range 3–42)
consisted of regular urology visits with PSA monitoring at 1,
3, 6, 9 and 12 months after treatment, followed by 3- to
6-month intervals. In addition, all patients underwent
follow-up prostate mpMRI at 3, 6 and 12 months after treat-
ment. All follow-up images were reviewed by one of two
prostate interventional radiologists (J.F. or S.J.). Any finding
suspected of indicating residual or recurrent tumour was sub-
sequently sampled by targeted in-bore MR-guided biopsy.
Furthermore, all patients received targeted in-bore
MR-guided biopsy directed at the ablation zone at 12 months
post-treatment from October 2013 onwards. Local tumour
progression after focal cryoablation was defined as evident
tumour recurrence on follow-up MRI, positive MR-guided
biopsy or biochemical failure according to Phoenix criteria
of PSA nadir + 2 ng/ml [23] without radiological evidence
of metastatic disease.
Statistical analysis
Statistics were performed using SPSS (version 20.0). Data are
reported as mean ± standard deviation unless indicated other-
wise. Baseline parameters were compared between cases of
local control and tumour progression using independent sam-
ples t test for normally distributed and Mann–Whitney U test
for non-normally distributed data. Chi-square analysis was
used for discrete data. Independent samples t test was used
to compare iceball margins by tumour volume and location.
Survival analysis was performed using the Kaplan–Meier
method. Log-rank test was used to assess differences between
survival curves. Cox proportional hazard univariable and mul-
tivariable models were used to assess pretreatment risk status,
prior ADT use and tumour volume as potential confounders
and determine whether iceball margins were independently
associated with local progression. Potential prognostic factors
with a P value less than 0.10 on univariable analysis were
included in the multivariable model. Outcomes were reported
as hazard ratios (HR) with 95% confidence intervals (CI) to
demonstrate level of precision. P values less than 0.05 were
considered statistically significant.
Results
A total of 47 cryoablation procedures were successfully per-
formed in 47 patients. A median of 3 cryoprobes (range 2–6)
were used per patient. Themedian iceball volume was 27.7 ml
(range 6.0–82.5). There were no intraprocedural complica-
tions. The median PSA nadir after focal prostate cryoablation
was 0.6 ng/ml (range <0.02–40.0) and was reached at a me-
dian of 3 months (range 1–24) after treatment.
On follow-up, 24 of 47 patients (51%) were locally con-
trolled. Local tumour progression occurred in 23 patients
Table 1 Patient demographic data (N = 47)
Median (range) or n (%)
Age (years) 66 (52–79)
PSA level (ng/ml) 4.9 (0.7–31.0)
Form of primary RT
EBRT 29 (62)
Brachytherapy 17 (36)
EBRT + brachytherapy 1 (2)




Gleason score of recurrence
≤ 6 7 (15)
7 17 (36)
≥ 8 16 (34)







Prostate volume (ml) 23.5 (6.6–64.2)
Tumour localization
Transition zone 11 (23)
Peripheral zone and/or seminal vesicles 36 (77)
Tumour volume (ml) 1.1 (0.2–11.8)
EBRT external beam radiotherapy, ADT androgen-deprivation therapy,
NCCN National Comprehensive Cancer Network
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(49%), of whom 14 had a positiveMR-guided prostate biopsy,
seven experienced PSA failure without radiological evidence
of distant disease and two patients had evident tumour recur-
rence on follow-up MRI but were spared targeted biopsy be-
cause of detection of nodal or bone metastases on the same
scan. The median time between treatment and local tumour
progression was 12 months (range 3–42). After multidisci-
plinary consensus seven patients with local tumour progres-
sion received repeat treatment with MR-guided cryoablation.
Ten out of the 47 patients (21%) showed metastatic disease
progression, of whom six were locally controlled and four
patients also had evidence of local tumour progression.
The distribution of baseline parameters between cases of
local control and tumour progression is shown in Table 2. A
statistically significant difference was found in prior history of
ADT administration between the stable and local progression
group (5/24 vs. 11/23; P = .025). No difference was seen for
pretreatment PSA level, Gleason score and clinical stage.
Iceball margins
The mean iceball margins for focal cryoablation were 8.9 mm
(range −7.1 to 16.2), 10.1 mm (range 1.1–20.3) and 12.5 mm
(range −1.5 to 22.2) in anteroposterior, left–right and
craniocaudal directions respectively. The mean minimum
iceball margin per patient was 7.5 mm (range −7.1 to 14.2),
with the shortest margin most often occurring in
anteroposterior direction (49%). An iceball margin greater
than 5 mm in each direction was achieved in 34/47 (72%) of
patients. Negative margins occurred in three cases (6%).
Iceballs were well centred in all but one patient. The one
off-centre iceball occurred in a large tumour involving the
peripheral zone and seminal vesicles. The iceball was found
to be off-centre on retrospective review of the intraprocedural
images because the insertion angle of the cryoprobes was
incorrectly aligned with the tumour’s geometry, causing the
iceball to be off-centre at the prostatic base and seminal
vesicles.
When stratified by tumour volume and location, the aver-
age minimum iceball margin was significantly smaller for
tumours larger than 1 ml compared to tumours 1 ml or smaller
(5.8 ± 4.8 vs. 9.2 ± 3.4 mm; P = .008) (Fig. 2) and for posterior
versus anterior tumours (6.8 ± 4.7 vs. 9.8 ± 2.7 mm; P = .047)
(Fig. 3).
On Kaplan–Meier analysis, significantly improved local
tumour progression-free survival at 1 year after focal
cryoablation was seen between patients with minimum iceball
margin greater than 10 mm (100%), 5–10 mm (84%) and less
than 5 mm (15%) (P < .001) (Fig. 4). Representative cases
with and without local tumour progression after focal salvage
Fig. 1 Annotation of a tumour (outlined in white) on pretreatment axial
and sagittal T2-weighted, ADC and DCE prostate MR images and b
corresponding iceball (outlined in white) at the end of the second freeze
cycle on axial and sagittal intraprocedural T1-weighted images, with
urethral warming catheter in situ (arrowhead). c The iceball margin
(asterisk) was determined by subtracting the radii of the tumour
(yellow) and iceball (blue) along each direction
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cryoablation are shown in Figs. 5 and 6 respectively.
Univariable and multivariable Cox regression analyses are
shown in Table 3.Minimum iceball margin (P < .001), tumour
volume (P = .005) and prior ADT use (P = .014) showed sig-
nificant association with local outcome on univariable analy-
sis. On multivariable analysis, minimum iceball margin
(P = .004) and prior ADT use (P = .008) remained indepen-
dent predictors of local tumour progression.
Discussion
The concept of focal therapy is to treat a tumour focus with an
adequate margin while sparing as much surrounding healthy
tissue as possible [24]. In cryoablation, the lethal temperature
threshold is generally regarded to lie between −20 °C to
−40 °C, depending on freezing rate, freeze duration and the
repetition of freeze-thaw cycles [25]. With lethal temperatures
residing several millimetres behind the leading edge of the
freezing process [26], it is imperative to achieve a definitive
margin with sufficient ice extending beyond the tumour bor-
der to ensure effective tissue necrosis throughout the entire
target region. For renal cryoablation, studies have
recommended freezing to be applied for approximately 5–
6 mm beyond the tumour border to achieve suitably cold
end temperatures [18, 27, 28]. In contrast, another study sug-
gested that for liver cryoablation with a single cryoprobe a
margin up to 1 cm might not be sufficient [29], but the syner-
gistic effect of multiple cryoprobes was not studied [26, 30].
Furthermore, it is unclear how findings from other areas of
application, i.e. renal or liver cryoablation, apply to the pros-
tate salvage setting. Adding to this, uncertainty exists in
predicting tumour borders from MRI with respect to the true
histological tumour boundary. For primary PCa, one study has
recently shown that imaging-derived tumour boundaries from
prostate mpMRI tend to underestimate the histologically de-
termined tumour volume at prostatectomy [31]. The authors
concluded that a treatment margin extending 9 mm around an
MRI visible tumour would be required to ensure treatment of
the complete tumour volume during focal ablative therapy
[32]. A similar study investigating the accuracy of
MR-based prostate tumour delineations for radiotherapy plan-
ning recommended a margin of 5 mm to achieve adequate
coverage [33]. In the present work, MR imaging-derived
iceball margins were correlated with local outcome after focal
salvage prostate cryoablation. A high rate of early local
Table 2 Comparison of baseline
parameters Local control (N = 24) Local tumour progression (N = 23) P value
PSA level 6.8 (0.7–31.0) 7.1 (1.1–21.0) .566
Gleason score .604
≤7 14 (58) 10 (43)
>7 8 (33) 8 (35)
Unknown 2 (8) 5 (22)
Clinical stage .154
T2a–c 20 (83) 15 (65)
T3b 4 (17) 8 (35)
Prior ADT use .025
Yes 5 (21) 11 (48)
No 19 (79) 12 (52)
Values in parentheses are range or percentages
Fig. 3 Minimum iceball margin by anterior or posterior tumour locationsFig. 2 Minimum iceball margin stratified by tumour volume
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tumour progression (85% at 1 year) was noted when the
iceball margin around an MRI-visible recurrent prostate tu-
mour were less than 5 mm. These initial clinical data suggest
that a minimum 5-mm margin would be required for effective
focal salvage prostate cryoablation, with a wider margin
appearing desirable.
A notable finding was that the iceball margins varied sig-
nificantly with tumour location. In the posterior area of the
prostate it can be particularly challenging to achieve sufficient
ice coverage extending beyond the tumour boundary because
of its close proximity to the rectum. During ablation, adjacen-
cy of the iceball to the rectal wall was actively monitored in
the intraoperative MR images and freeze intensity was mod-
ulated accordingly to avoid unwanted damage to the rectal
wall. Also, the rectum was actively warmed with warm saline
using a rectal balloon, which may explain the lower iceball
margins achieved in posterior tumours. For these tumour lo-
calizations, critical preoperative assessment of the ability to
achieve adequate ablation margins should be performed in
each individual case. Additionally, displacement of the rectum
using hydrodissection may be considered to obtain increased
spacing between the prostate and rectal wall and allow for a
wider ablation margin.
Fig. 5 Representative case of local tumour progression after MR-guided
focal salvage cryoablation. a Pretreatment axial T2-weighted, ADC and
DCE images show a hypointense lesion with diffusion restriction and
focal enhancement in the prostatic base extending into the seminal
vesicles after primary radiotherapy. Local PCa recurrence was
histologically confirmed with in-bore MR-guided biopsy. Annotated
tumour boundary is overlaid (white outline). b Corresponding
intraprocedural axial T1-weighted image during MR-guided cryoablation
shows the final frozen zone at the end of the second freeze cycle, with
annotated iceball boundary overlaid (white outline). Urethral warming
catheter is indicated (arrowhead). c 12-month follow-up MRI shows
hypointense signal on axial T2-weighted images with diffusion restriction
and focal enhancement in the seminal vesicles. Local recurrence after
cryoablation was confirmed on targeted in-bore MR-guided biopsy. d
Retrospective review of this case showed a minimum iceball margin of
−7.1 mm, with insufficient coverage in anteroposterior direction
Fig. 4 Local progression-free survival stratified by minimum iceball
margin <5mm, 5–10mm and >10mm,with corresponding numbers at risk
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There also was a significant difference in the average iceball
margin depending on tumour volume. However, substantial
overlap can be seen between the margins achieved in the larger
(>1 ml) and smaller (<1 ml) lesions and successful ablations
were achieved in tumours up to 3.3 ml in volume when a 5-mm
margin was achieved. Likewise, local tumour progression oc-
curred after ablation of lesions as small as 0.3 ml when the
margin was insufficient in one direction. Together, these find-
ings suggest that even though it is more difficult to achieve
wide ablation margins in larger tumours, successful ablation
can be achieved. In addition, in small tumours, the need for
an adequate iceball margin remains important.
Of baseline parameters, prior history of ADT use was sig-
nificantly different between cases of local control and tumour
progression and demonstrated significant association with
local tumour progression on multivariate analysis as well.
Although large randomized studies have shown ADT to im-
prove cancer-specific and overall survival when given
neoadjuvantly to primary radiation [34, 35], the exact role of
ADT before salvage treatment has not been well defined. An
early study has investigated the effect of the combination of
androgen deprivation with salvage surgery in patients with
radiorecurrent prostate cancer and suggested that patients in
whom an initial trial of ADT failed were poor candidates for
salvage prostatectomy [36]. Similarly, for whole-gland sal-
vage prostate cryoablation one study has recently shown that
patients receiving ADT before salvage cryoablation had worse
5-year biochemical progression-free survival [37]. One expla-
nation is that the initiation of ADT before salvage cryoablation
may have concealed rising PSA levels, masking
Fig. 6 Representative case of local tumour control. a Pretreatment axial
T2-weighted, ADC and DCE images demonstrate a histologically
confirmed local PCa recurrence with diffusion restriction and focal
enhancement in the ventral transition zone (white outline) after primary
brachytherapy. b Intraprocedural axial T1-weighted image shows the
final frozen zone (white outline) at the end of the second freeze cycle,
with urethral warming catheter indicated (arrowhead). c 12-month
follow-up MRI shows hyperintense signal on axial T2w images without
diffusion restriction at the ventral transition zone. DCE images show a
non-perfused area at the same location that coincides with the treated area.
Targeted in-bore MR-guided biopsy directed at the ablation area showed
no evidence of malignancy. d The retrospective review of this case
showed adequate coverage in all directions, with the minimum iceball
margin being 9.4 mm
Table 3 Cox regression analysis
of predictors of local progression Univariable P value Multivariable P value
HR (95% CI) HR (95% CI)
Min. iceball margin 0.85 (0.78–0.93) <.001 0.85 (0.77–0.95) .004
Tumour volume 1.25 (1.07–1.45) .005 1.08 (0.91–1.28) .40
Prior ADT use 0.35 (0.15–0.81) .014 0.30 (0.12–0.73) .008
NCCN risk category 1.67 (0.70–3.97) .25 –
4834 Eur Radiol (2017) 27:4828–4836
micrometastatic disease progression. Consequently, at the
time of salvage cryoablation patients with systemic disease
may be unintentionally subjected to local salvage treatment.
Possibly, the latter is corroborated by the substantial pro-
portion of patients diagnosed with metastatic disease progres-
sion during follow-up of the present study (21%). All but two
of these instances occurred within the first 12 months after
focal salvage treatment and metastatic work-up may have
been false negative in these patients, with current imaging
techniques having limited sensitivity [38]. Improved metasta-
tic screening using new contrast agents such as iron
nanoparticles-enhanced MR lymphography [38, 39] or
gallium-68-PSMA PET-CT [40] to specifically evaluate
lymph node status may be imperative to better select suitable
candidates for local salvage treatment.
The most important limitation of our study was that iceball
margins were only calculated in three directions and assumed
the iceball to be well centred with respect to the tumour to
register the annotated regions. In some patients, margins may
not necessarily have been symmetrical and there could be a
sufficient margin on one side but an insufficient margin on the
other side when a tumour was not centrally located within the
ablation zone. Ideally, all pretreatment images would be ex-
actly matched to the intraprocedural data to provide an im-
proved assessment of the 3D ablation margin. In our experi-
ence, however, direct registration of the image sets will not
necessarily be accurate because of prostate deformation from
cryoprobe insertion or movement of the entire gland due to the
rectal balloon, and adequate methods to address these errors
are needed to provide a more detailed characterization of the
true ablation margin in future studies.
Other limitations to this work include its retrospective na-
ture and short- to intermediate-term follow-up. Also, there is
currently no universally accepted definition of tumour recur-
rence following local prostate salvage treatments. The
Phoenix definition is the most commonly reported criterion
in this setting and in one study was found to more accurately
predict local cancer recurrence following prostate
cryoablation than American Society for Therapeutic
Radiotherapy and Oncology (ASTRO) criteria [41]. Imaging
follow-up of the prostate after focal therapy using mpMRI has
also been increasingly applied, with functional techniques
showing promise to detect local PCa recurrence after therapy
[42]. In this study, both biochemical as well as mpMRI and
biopsy findings were integrated into a combined definition of
local tumour progression. Ultimately, a standardized defini-
tion would need to be identified to facilitate direct comparison
of studies evaluating prostate focal ablation techniques.
Finally, heterogeneity can be seen in our patient cohort with
respect to presalvage PSA levels, Gleason scores and clinical
stage. Our findings require validation on multivariable analy-
sis in more patients and with longer follow-up to come to
definitive conclusions.
In conclusion, iceball margins appear correlated with local
outcome following MR-guided focal salvage prostate
cryoablation. Our initial data suggest that a minimum margin
of 5 mm should be achieved around an MR-visible recurrent
tumour for successful ablation, with a wider margin being
desirable. Adequate margins may be more difficult to achieve
in tumours that are larger and located posteriorly, which may
be an important factor to consider when selecting candidates
for focal salvage treatment after previous RT.
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